Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
 

 

TTD Drug ID: DAP000328

Drug Information
NameTripelennamine    
SynonymsHSDB 5191; Pyridine, 2-(benzyl(2-(dimethylamino)ethyl)amino)-; 91-81-6; Tripellenamine; N,N-Dimethyl-N'-benzyl-N'-(2-pyridyl)ethylenediamine; WLN: T6NJ BN1R&2N1&1 &GH; Tripelenamine; BSPBio_003252; KBioGR_000867; C16H21N3; Dehistin; Tripelennamina [Italian]; KBio2_000621; Spectrum2_000957; CID5587; Tripelenamina [INN-Spanish]; beta-Dimethylaminoethyl-2-pyridylbenzylamine; KBio2_003189; N-Benzyl-N',N'-dimethyl-N-(2-pyridyl)ethylenediamine; L000603; N,N-Dimethyl-N'-(phenylmethyl)-N'-2-pyridinyl-1,2-ethanediamine; Cizaron; DivK1c_000534; Benzoxale; KBioSS_000621; LS-130287; Pyridbenzamine; Tripelennamin; nchembio747-comp17; Benzyl-(alpha-pyridyl)-dimethylaethylendiamin; C07180; Tripelennamine (INN); tripelennamine; 5-22-08-00378 (Beilstein Handbook Reference); KBio3_002472; Tripelennamina; 2-[Benzyl(2-dimethylaminoethyl)amino]pyridine; AC1L1KOH; DB00792; Tripelennaminum [INN-Latin]; Pyribenzamin; N,N-dimethyl-N'-(phenylmethyl)-N'-pyridin-2-ylethane-1,2-diamine; 58044-99-8 (maleate (1:1)); Tripelennamine Citrate (1:1); 2750 R.P.; Spectrum_000141; N-Benzyl-N-(2-pyridyl)-N',N'-dimethyl ethylenediamine; BRD-K57033106-048-02-8; N,N-Dimethyl-N'-benzyl-N'-(alpha-pyridyl)ethylenediamine; NCI-C60662; Benzyl-(alpha-pyridyl)-dimethylaethylendiamin [German]; Benzyl-(.alpha.-pyridyl)-dimethylaethylendiamin; 2-(benzyl(2-(dimethylamino)ethyl)amino)pyridine; Tripelennamine [INN]; Oprea1_266730; Pyribenzamine; 6138-56-3 (citrate (1:1)); KBio2_005757; Tripelennaminum; Vetibenzamina; Pyridine, 2-[benzyl[2-(dimethylamino)ethyl]amino]-; Piribenzil; N-Benzyl-N',N'-Dimethyl-N-Pyridin-2-Yl-Ethane-1,2-Diamine Hydrochloride; Spectrum4_000374; Triplennamine; Pyristine (piristina); IDI1_000534; N-Benzyl-N',N'-dimethyl-N-2-(pyridylethylene)diamine; Tonaril; N'-benzyl-N,N-dimethyl-N'-pyridin-2-ylethane-1,2-diamine; N,N-Dimethyl-N'-benzyl-N'-(.alpha.-pyridyl)ethylenediamine; Tripelannamine; CHEMBL1241; Spectrum5_001581; N-Benzyl-N',N'-dimethyl-N-2-pyridylethylenediamine; 2-[N-Benzyl-N-(2-dimethylaminoethyl)amino]pyridine; KBio1_000534; Tripelenamina; Pyrinamine base; UNII-3C5ORO99TY; beta-Dimethylaminoethyl-2-pyridylaminotoluene; D08645; Ethylenediamine, N-benzyl-N',N'-dimethyl-N-(2-pyridyl)-; NINDS_000534; N-benzyl-N-[2-(dimethylamino)ethyl]pyridin-2-amine; EINECS 202-100-1; NCGC00018125-01; BRN 0227074; Tripelennamine [BAN]; MolPort-001-785-598; 2750 R.P; .beta.-Dimethylaminoethyl-2-pyridylaminotoluene; 2-(Benzyl(2-dimethylaminoethyl)amino)pyridine; SPBio_000954; 22306-05-4 (hydrochloride); .beta.-Dimethylaminoethyl-2-pyridylbenzylamine; Resistamine; NSC118946; AC1Q3WSJ; 154-69-8 (mono-hydrochloride); 1,2-Ethanediamine, N,N-dimethyl-N'-(phenylmethyl)-N'-2-pyridinyl-; NSC 118946; Ts and Blues; Benzyl-.alpha.-pyridyl-dimethyl-aethylendiamin; WLN: T6NJ BN1R&2N1&1; AC1Q3WSI; Spectrum3_001696; 1,2-Ethanediamine, N,N-dimethyl-N'-(phenylmethyl)-N'-2-pyridinyl- (9CI); 2-(N-Benzyl-N-(2-dimethylaminoethyl)amino)pyridine    
Trade NamePyribenzamine    
CompanyNorvatis Phamaceuticals Corporation    
IndicationAsthmaApproved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
   
Therapeutic ClassAnti-Allergic Agents    
CAS NumberCAS 91-81-6
FormularC16H21N3    
PubChem Compound IDCID 5587.    
PubChem Substance IDSID 9389.    
SuperDrug ATC IDD04AA04;    
SuperDrug CAS ID000091816;    
TargetHistamine H1 receptorAntagonist[2][3][4][5]
Ref 1FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 080713 To Reference
Ref 2Involvement of histamine H1 and H2 receptors in the regulation of STAT-1 phosphorylation: inverse agonism exhibited by the receptor antagonists. Int Immunopharmacol. 2005 Jul;5(7-8):1299-309. To Reference
Ref 3Role of N-methyl-D-aspartate receptors in gastric mucosal blood flow induced by histamine. J Neurosci Res. 2004 Sep 1;77(5):730-8. To Reference
Ref 4Prostaglandin E2 aggravates gastric mucosal injury induced by histamine in rats through EP1 receptors. Life Sci. 2003 Dec 19;74(5):629-41. To Reference
Ref 5Histamine H1 and H2 receptor antagonists accelerate skin barrier repair and prevent epidermal hyperplasia induced by barrier disruption in a dry environment. J Invest Dermatol. 2001 Feb;116(2):261-5. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

 
   
           
 
Computer-aided Drug Design
About BIDD | Databases | Software | Teaching | Research |  Links

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543